Imricor Initiates U.S. Commercial Operations with Rady Children's Hospital as Premier Client

Rady Children's Hospital Selection and Clinical Importance

Rady Children's Hospital–San Diego, renowned for one of the nation’s top pediatric cardiology programs, marks a strategically vital first customer for Imricor’s U.S. commercial debut. The hospital’s adoption of NorthStar demonstrates strong clinical confidence in the technology and highlights the significant benefits of radiation-free iMR guidance for pediatric patients. Rady Children's commitment to being the first U.S. hospital to perform cardiac catheterisation entirely guided by NorthStar’s radiation-free iMR system sets a precedent likely to influence other U.S. hospitals as clinical evidence and awareness grow.

For pediatric patients with congenital heart defects who often require repeated catheterisations from infancy through adulthood, eliminating exposure to ionizing X-ray radiation is critically important. Imricor’s technology also offers enhanced soft tissue visualization and richer functional data, such as blood flow and cardiac output, compared to conventional X-ray fluoroscopy. Rady Children's initial use of NorthStar for cardiac catheterisation is the first step in a broader radiation-free clinical pathway, with plans to extend applications to electrophysiology and ablation procedures, further increasing Imricor’s technology footprint within the hospital.

FDA Approvals and Regulatory Progress

Imricor’s U.S. commercial launch follows rapid regulatory achievements that enabled market entry. In January 2026, the FDA granted 510(k) clearances for the Vision-MR Diagnostic Catheter—Imricor’s first U.S. clearance—and for NorthStar, the world’s first and only iMR 3D mapping and guidance system. These initial clearances were limited to specific patient groups, restricting early market access. However, in July 2026, the FDA approved pediatric label expansions for both products, allowing use in patients of all ages and substantially broadening the U.S. addressable market.

The pediatric label expansions represent a pivotal regulatory milestone, transforming Imricor’s commercial prospects. With clearance for patients of any age, Imricor can now target over 250 children’s hospitals and more than 2,000 adult hospitals performing cardiac catheterisation across the United States. This expanded indication removes a major regulatory barrier and opens access to a significantly larger market for Imricor’s products nationwide.

Introduction of Imricor Cardiovascular Business Segment

Following FDA approvals and label expansions, Imricor has launched Imricor Cardiovascular, a new business vertical focused on cardiac catheterisation procedures utilizing NorthStar technology. This initiative creates a new market alongside Imricor’s existing electrophysiology and ablation business, reflecting a strategic effort to leverage its iMR platform across multiple cardiac applications and serve a broader hospital customer base beyond its prior electrophysiology focus.

The expansion into cardiovascular applications is driven by the clinical and economic advantages of MR-guided cardiac catheterisation for hospital systems. With NorthStar and Vision-MR Diagnostic Catheter now cleared for all ages, Imricor can address a much larger market than previously possible. The company anticipates adding more devices and applications within the Cardiovascular segment over time, indicating a multi-product strategy that diversifies revenue streams and reduces reliance on its established electrophysiology business.

Hospital Economics and Operational Advantages of iMR-Guided Procedures

Imricor’s update emphasizes strong hospital economic benefits underpinning its commercial value proposition. Traditionally, cardiac catheterisation patients undergo separate MRI scans and X-ray lab procedures on different days, each requiring full clinical teams and facility setups. Combining these into a single interventional MR lab session yields approximately 35% procedural time savings per patient and lowers operational costs. These efficiencies translate into tangible financial benefits hospital administrators can quantify when considering technology adoption.

Additionally, capacity utilization improves as routine cardiac catheterisations shift to the iMR lab, freeing X-ray cath lab availability for other interventional procedures. This capacity unlocks opportunities for higher-margin interventions that generate significant additional revenue, strengthening the financial rationale for hospitals to adopt Imricor’s technology. The company positions NorthStar not only as a clinical improvement but also as a tool to enhance hospital operational efficiency and productivity.

Growing Commercial Momentum and Pipeline of Hospital Customers

Beyond Rady Children’s, Imricor reports several U.S. hospitals in advanced stages of purchase negotiations, expected to acquire NorthStar in the coming weeks. This growing interest indicates expanding market acceptance and suggests Rady Children’s selection may catalyze broader adoption as other hospitals witness clinical and operational benefits.

To support this growth, Imricor is scaling its U.S. commercial team by hiring an additional Capital Sales Manager for the Southeast region, along with more sales representatives and internal sales operations staff. This expansion reflects management’s confidence in near-term demand and addresses the operational needs of managing multiple hospital accounts, navigating complex procurement, and supporting implementation and training across diverse U.S. regions.

Revenue Projections and Financial Impact for Fiscal 2025

Imricor disclosed that NorthStar sales revenue in the U.S. is expected to surpass the combined full-year revenue of its European business in 2025. While specific figures were not provided, this comparison signals a substantial commercial impact from the U.S. launch and highlights the strategic importance of the U.S. market to Imricor’s financial performance. The guidance implies multiple hospital customers will onboard during 2025, aligning with the company’s statement regarding hospitals in final purchasing stages.

This revenue outlook establishes a near-term financial benchmark for evaluating the success of Imricor’s U.S. commercial launch in upcoming investor communications and financial reports.

Market Potential: Pediatric and Adult Hospital Segments

Imricor’s U.S. addressable market significantly exceeds its prior European focus. With FDA clearances and pediatric label expansions, the company can serve over 250 children’s hospitals and more than 2,000 adult hospitals performing cardiac catheterisations nationwide. This combined market of over 2,250 hospitals represents a major expansion from Imricor’s previous pediatric and electrophysiology-centric customer base, providing a foundation for sustained revenue growth and customer acquisition.

The pediatric segment is strategically valuable due to the lifelong need for repeated cardiac catheterisations in children with congenital heart disease, creating recurring revenue and long-term customer value. The adult hospital market offers high-volume opportunities, as cardiac catheterisation is widely performed, and the economic benefits of iMR guidance apply equally to pediatric and adult patients. This dual-market approach supports a diversified customer acquisition strategy across hospital types and regions.

Management Outlook and Strategic Direction

Imricor’s update conveys strong management confidence in the long-term commercial viability of its technology and its ability to compete in the U.S. medical device market. The establishment of Imricor Cardiovascular as a dedicated vertical signals a strategic shift to broaden the company’s addressable market beyond electrophysiology and ablation. Management’s intention to continue expanding devices and applications within Cardiovascular suggests a multi-year roadmap aimed at positioning Imricor as a comprehensive cardiovascular iMR technology provider.

The planned expansion of the U.S. commercial team reflects commitment to supporting sustained growth and market penetration. These hiring plans represent increased operating expenses but demonstrate confidence that the customer pipeline will generate sufficient revenue to justify the investment. Investors should monitor future financial results to evaluate whether customer acquisition and revenue align with management’s expectations.

Competitive Landscape and Technological Differentiation

Imricor markets NorthStar as the world’s first and only iMR 3D mapping and guidance system, offering significant competitive differentiation in cardiac catheterisation guidance. While X-ray fluoroscopy remains the standard in most U.S. hospitals, Imricor’s radiation-free MR-guided alternative could disrupt the market if clinical outcomes and hospital economics prove favorable. The technology’s benefits—including elimination of ionizing radiation, enhanced soft tissue visualization, and richer functional data—address critical unmet needs, especially for pediatric patients requiring multiple procedures.

Nevertheless, the medical device sector is highly competitive. Imricor’s first-mover advantage may face challenges from larger companies with established hospital relationships and resources, who could develop competing iMR or alternative radiation-free guidance technologies. Maintaining market share and expanding the addressable market will depend on ongoing clinical evidence, sustained regulatory approvals, and effective commercial execution in a competitive environment.